ARMY AL&T
EXPEDITED T
DELIVERY
JPEO-CBRND fills a gap in Europe with the rapid delivery of a lifesaving antidote.
by Meg Holahan, Alex Hillman and Kelly Burkhalter
he Russian invasion of Ukraine on Feb. 24, 2022, shocked the world, touch- ing off the largest armed conflict in Europe since World War II. Between the unknown of an escalating war and the inability to predict Russia’s next move, the invasion put nations across the continent and the world on high alert.
DOD began moving quickly to ensure that U.S. forces in the U.S. European Command (EUCOM) area of responsibility remain prepared for any potential battlefield scenario. Te joint force needs to be prepared to fight through any situation around the world, from large-scale combat operations to invisible threats that can incapacitate in seconds.
Since the conflict in Ukraine began, there has been persistent concern about the potential use of chemical weapons, including opioids such as fentanyl and carfentanil. Opioids are highly potent and extremely dangerous. Exposure poses a significant risk to the joint force, as even extremely small doses of these substances—amounts equivalent to a few grains of salt—can cause breathing difficulties and even death in less than 10 minutes.
OPIOIDS AS A BATTLEFIED THREAT Russia has a well-documented history of using unconventional means to defeat any adver- sary, including the suspected use of chemical, biological and radiological agents. In 2002, one or more chemical agents (believed to be fentanyl derivatives) were used to end a hostage crisis at a large, crowded theater in Moscow. Te incident resulted in several hundred civil- ian casualties. In 2018, Russian operatives used a Novichok nerve agent to poison former Russian military officer turned British spy Sergei Skripal and his daughter, Yulia, in Salis- bury, England, and used Novichok again in 2020 to poison Russian opposition leader Alexei Navalny.
Te U.S. Chemical and Biological Defense program, recognizing the potential threat opioids could be for warfighters and the need for a rapid solution, directed its advanced development component, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), to develop a medical countermeasure against this evolving threat. JPEO-CBRND’s Joint Project Manager for CBRN Medical Chemical
https://asc.ar my.mil 37
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136
